Consultee Information Sheet

Title of Study: The effect of early cryoprecipitate transfusion versus standard care in women who develop severe postpartum haemorrhage: A pilot cluster randomised trial (ACROBAT: Administering CRyoprecipitate in Obstetric Bleeding At an earlier Time)

Chief Investigator: Dr Laura Green. **Sponsor:** Queen Mary University of London

Why am I being given this leaflet?

This hospital is taking part in a research study to investigate a treatment for Postpartum Haemorrhage (PPH), a condition where there is heavy bleeding in pregnant women after childbirth, requiring blood transfusion. This research will help us understand how best to improve the care of women who suffer heavy bleeding during childbirth in the future.

The attached Participant Information Sheet contains the full information of what the study entails and what participation means. The study is for women who have severe bleeding in childbirth. It looks at giving a standard blood product, called cryoprecipitate, earlier in the course of bleeding, in some of the participating hospitals. Because this is an emergency treatment, it is not possible to get informed consent from participants beforehand, as this would delay a potentially life-saving treatment.

Unfortunately the patient is currently too unwell to give consent to continue participating in this study. That is why we are asking your opinion of the patient's wishes or feelings as to whether to continue to participate in this study. Please read the attached Participant Information Sheet (which is addressed directly to participants). You are free to decide whether you wish to make this decision or not. Take time to decide whether or not you wish her to continue to participate in this research study.

Please let us know of any advance decisions they may have made about participating in research. These should take precedence.

What would participating in this study mean for the patient?

This would simply allow us to collect de-identified routine medical data about the participant's treatment to the study, and transfer it to the study organisers for analysis.

If you decide the patient would have no objection to continuing to take part, we will ask you to sign the consultee declaration below. If you decide that the patient would not wish to take part, it will not affect the standard of care they receive in any way. If you are unsure about taking the role of consultee you may seek independent advice. We will understand if you do not want to take on this responsibility.

Consultee Declaration:

I agree for _____ to be included in the ACROBAT for the purpose of data collection.
Name of participant

_____	_____	_____
Name of consultee	Signature	Date

Relationship of consultee to participant: _____

_____	_____	_____
Name of researcher	Signature	Date